Zomedica Corp.

Equities

ZOM

CA98980M1095

Healthcare Facilities & Services

Market Closed - Nyse Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
0.1737 ^USD	-5.75%		+9.31%	-13.24%

05-15	Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform	CI
05-09	Earnings Flash (ZOM) ZOMEDICA Posts Q1 Revenue $6.3M	MT

Zomedica Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 11, 2023 at 09:16 pm

Zomedica Corp. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported sales was USD 5.48 million compared to USD 3.75 million a year ago.

Net loss was USD 6.39 million compared to USD 3.94 million a year ago. Basic loss per share from continuing operations was USD 0.007 compared to USD 0.004 a year ago. Diluted loss per share from continuing operations was USD 0.007 compared to USD 0.004 a year ago.

Latest news about Zomedica Corp.

Zomedica Corp. Releases Over-The-Air Software Update Capabilities for Its Truforma(R) Platform	05-15	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q1 Revenue $6.3M	05-09	MT
Transcript : Zomedica Corp., Q1 2024 Earnings Call, May 09, 2024	05-09
Zomedica Corp. Provides Revenue Guidance for Full Year 2024	05-09	CI
Zomedica Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Zomedica Seeks Acquisitions	04-01	CI
Transcript : Zomedica Corp., Q4 2023 Earnings Call, Apr 01, 2024	04-01
Earnings Flash (ZOM) ZOMEDICA Posts Q4 Revenue $7.3M	04-01	MT
Zomedica Corp. Reiterates Revenue Guidance for Full Year 2024	04-01	CI
Zomedica Corp. Announces Publication of Research Con Including TRUFORMA(R) Platform Is More Accurate Diagnostic Test for Feline Hyperthyroidism Than Chemiluminescent Immunoassay Platform	03-14	CI
Transcript : Zomedica Corp. - Shareholder/Analyst Call	02-28
Transcript : Zomedica Corp. - Analyst/Investor Day	02-13
Zomedica Pharmaceuticals Reports Preliminary Q4 Revenue	01-17	MT
Transcript : Zomedica Corp., 2023 Sales/ Trading Statement Call, Jan 17, 2024	01-17
Zomedica Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Full Year 2024	01-17	CI
Zomedica Corp. Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease	12-18	CI
Zomedica Announces Presentation of Clinical Data in Support of New Indications for Pulsevet Shock Wave Therapy	12-06	CI
Earnings Flash (ZOM) ZOMEDICA Posts Q3 Revenue $6.3M	11-13	MT
Transcript : Zomedica Corp., Q3 2023 Earnings Call, Nov 13, 2023	11-13
Zomedica Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13	CI
Zomedica Corp. acquired Qorvo Biotechnologies, LLC from Qorvo US, Inc. for $11.3 million.	04/10/23	CI
Zomedica Corp. Launches its Newest Assay - Endogenous ACTH	14/09/23	CI
Zomedica Pharmaceuticals Issued Warning From NYSE American For Failing to Meet Listing Requirement	13/09/23	MT
Zomedica Completes Acquisition of Structured Monitoring Products	05/09/23	MT
Earnings Flash (ZOM) ZOMEDICA Posts Q2 Revenue $6M	10/08/23	MT

Chart Zomedica Corp.

Duration

Period

More charts

Company Profile

Zomedica Corp. is a veterinary health company. The Company is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The Company's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.

Sector

Healthcare Facilities & Services

Calendar

05/06/2024 - ACVIM Forum

More about the company